| | 955365-80-7 Basic information More.. |
| Product Name: | MK-1775 | | Synonyms: | 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one;MK-1775;MK-1775,MK1775;2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1,2-dihydropyrazolo[3,4-d]pyrimidin-3-one;2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one MK 1775;MK 1775
2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one;MK-1775, >=98%;MK-1175 | | CAS: | 955365-80-7 | | MF: | C27H32N8O2 | | MW: | 500.6 | | EINECS: | | | Mol File: | 955365-80-7.mol |  |
Use
MK-1775 is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. MK-1775 selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDK1, CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents.
MK-1775 is a type of biological therapy. It is a cancer growth blocker. It stops signals that cancer cells use to divide and grow.
MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.
- MK-1775
-
- US $0.00 / KG
- 2022-01-14
- CAS:955365-80-7
- Min. Order: 1KG
- Purity: 98.1%
- Supply Ability: 100 tons
- Adavosertib
-
- US $1.50 / g
- 2021-11-15
- CAS:955365-80-7
- Min. Order: 100g
- Purity: 99%
- Supply Ability: 500ton/Month
- MK-1775
-
- US $1.10 / g
- 2021-09-28
- CAS:955365-80-7
- Min. Order: 1g
- Purity: 99.00%
- Supply Ability: 100 Tons Min
|
|
955365-80-7
Recommend Suppliers |
|